ÂÜÀòÂÒÂ×

Julie Grant is a seasoned professional in the biotechnology and investment sectors, currently serving as a General Partner at Canaan since July 2013, where additional roles have included Partner, Principal, and Associate. Involved with Synthekine and Nocion Therapeutics, Inc. as a Board Member since March 2019 and February 2018 respectively, Julie also chaired the board of Day One Biopharmaceuticals from November 2018 to June 2023, after co-founding and leading the company as Chief Executive Officer. Previous board affiliations include Glooko as a Board Observer, the Biden Cancer Initiative, Chrono Therapeutics, and Protagonist Therapeutics. Julie holds an MBA from Stanford University Graduate School of Business, an MPhil in BioScience Enterprise from the University of Cambridge, and a B.S. in Molecular Biophysics and Biochemistry from Yale University.